» Articles » PMID: 16459097

Protective Effects of Isoliquiritigenin in Transient Middle Cerebral Artery Occlusion-induced Focal Cerebral Ischemia in Rats

Overview
Journal Pharmacol Res
Publisher Elsevier
Specialty Pharmacology
Date 2006 Feb 7
PMID 16459097
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Epidemiological studies indicate that the intake of flavonoids is inversely associated with risk of stroke, cardiovascular diseases and cancer. Isoliquiritigenin (ISL), a flavonoid constituent in the root of Glycyrrhiza glabra, is known to have vasorelaxant effect, antioxidant, anti-platelet, anti-tumor, anti-allergic, antiviral activities and estrogenic properties. However, there is no report on the effects of ISL in cerebral ischemia. Evidence demonstrate that the impaired energy metabolism and the excessive generation of reactive oxygen radicals (ROS) contribute to the brain injury associated with cerebral ischemia. In the present study, the protective effects of ISL were investigated in transient middle cerebral artery occlusion (MCAO)-induced focal cerebral ischemia-reperfusion injury in rats. Male Sprague-Dawley rats were divided into five groups: sham-operated group, vehicle-pretreated group, and three ISL-pretreated groups (5, 10 and 20 mg kg(-1), i.g.). ISL were administered once a day, for 7 days prior to ischemia. The rats were subjected to 2 h right MCAO via the intraluminal filament technique and 22 h reperfusion. Pretreatment with ISL significantly reduced the cerebral infarct volume and edema and produced significant reduction in neurological deficits. In this study, in order to clarify the mechanism of ISL's protection against cerebral ischemia damage, cerebral energy metabolism, brain Na+K+ATPase activity, malondialdehyde (MDA) content and antioxidant enzyme activities were measured. ISL pretreatment increased the brain ATP content, energy charge (EC) and total adenine nucleotides (TAN) in a dose-dependent manner. The brain Na+K+ATPase activity was protected significantly by pretreatment of ISL for 7 days. Pretreatment with ISL significantly inhibited the increases of brain MDA content and prevented the activities of brain superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) from declines caused by cerebral ischemia-reperfusion. All these findings indicate that ISL has the protective potential against cerebral ischemia injury and its protective effects may be due to the amelioration of cerebral energy metabolism and its antioxidant property.

Citing Articles

Isoliquiritigenin alleviates cerebral ischemia-reperfusion injury by reducing oxidative stress and ameliorating mitochondrial dysfunction via activating the Nrf2 pathway.

Lan X, Wang Q, Liu Y, You Q, Wei W, Zhu C Redox Biol. 2024; 77:103406.

PMID: 39454290 PMC: 11546133. DOI: 10.1016/j.redox.2024.103406.


Isoliquiritigenin attenuates myocardial ischemia reperfusion through autophagy activation mediated by AMPK/mTOR/ULK1 signaling.

Shen L, Zhu Y, Chen Z, Shen F, Yu W, Zhang L BMC Cardiovasc Disord. 2024; 24(1):415.

PMID: 39123142 PMC: 11311884. DOI: 10.1186/s12872-024-04054-z.


Neuroprotective effects of methanolic extract from Chuanxiong Rhizoma in mice with middle cerebral artery occlusion-induced ischemic stroke: suppression of astrocyte- and microglia-related inflammatory response.

Lim C, Lim S, Moon S, Cho S BMC Complement Med Ther. 2024; 24(1):140.

PMID: 38575941 PMC: 10993527. DOI: 10.1186/s12906-024-04454-w.


Preparation of novel S-allyl cysteine chitosan based nanoparticles for use in ischemic brain treatment.

Khan M, Ahmad N, Alkholifi F, Ullah Z, Khalid M, Akhtar S RSC Adv. 2024; 14(1):160-180.

PMID: 38173594 PMC: 10759039. DOI: 10.1039/d3ra05933b.


Amelioration of Brain Damage after Treatment with the Methanolic Extract of in Mice.

Choi M, Lim C, Lee B, Cho S Pharmaceutics. 2022; 14(12).

PMID: 36559268 PMC: 9781260. DOI: 10.3390/pharmaceutics14122776.